Timothy E. Wilens

Timothy E. Wilens

Auto-generated profile, based on publicly available information

Timothy E. Wilens

Massachusetts General Hospital, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
PDF file
TWTimothy E. Wilens
Timothy E. Wilens
LALenard A. Adler
Lenard A. Adler
JAJill Adams
Jill Adams
SSStephanie Sgambati
Stephanie Sgambati
JRJohn Rotrosen
John Rotrosen
SFSteven Fusillo
Steven Fusillo

1 September 2010 in Postgraduate Medicine
Verified
Journal Article
Closed access
TWTimothy E. Wilens
Timothy E. Wilens
TSThomas J. Spencer
Thomas J. Spencer
Attention deficit/hyperactivity disorder (ADHD) is among the most common neurobehavioral disorders requiring treatment in children and adolescents. The disorder is often chronic, with prominent sym...

1 June 2011 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
TWTimothy E. Wilens
Timothy E. Wilens
MMMaryKate Martelon
MaryKate Martelon
GJGagan Joshi
Gagan Joshi
CBClancey Bateman
Clancey Bateman
RFRonna Fried
Ronna Fried
JBJoseph Biederman
Joseph Biederman

15 November 2009 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
TWTimothy E. Wilens
Timothy E. Wilens
JBJoseph Biederman
Joseph Biederman
SFStephen V. V Faraone
Stephen V. V Faraone
MMMaryKate Martelon
MaryKate Martelon
DWDiana Westerberg
Diana Westerberg
TSThomas J. Spencer
Thomas J. Spencer
Despite the increasing presentation of attention-deficit/hyperactivity disorder (ADHD) in adults, many practitioners remain reluctant to assess individuals for ADHD, in part related to the relative lack of data on the presenting symptoms of ADHD in adulthood. Comorbidity among adults with ADHD is also of great interest due to the high rates of psychiatric comorbidity, which can lead to a more persistent ADHD among adults. We assessed 107 adults with ADHD of both sexes (51% female; mean +/- SD of 37 +/- 10.4 years) using structured diagnostic interviews. Using DSM-IV symptoms, we determined DSM-IV subtypes. The study was conducted from 1998 to 2003. Inattentive symptoms were most frequently endorsed (> 90%) in adults with ADHD. Using current symptoms, 62% of adults had the combined subtype, 31% the inattentive only subtype, and 7% the hyperactive/impulsive only subtype. Adults with the combined subtype had relatively more psychiatric comorbidity compared to those with the predominately inattentive subtype. Women were similar to men in the presentation of ADHD. Adults with ADHD have prominent inattentive symptoms of ADHD, necessitating careful questioning of these symptoms when evaluating these individuals.

1 April 2020 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
HBHeidi Boland
Heidi Boland
MDMaura DiSalvo
Maura DiSalvo
RFRonna Fried
Ronna Fried
KWK. Yvonne Woodworth
K. Yvonne Woodworth
TWTimothy Wilens
Timothy Wilens
JBJoseph Biederman
Joseph Biederman

1 June 2008 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
TWTimothy E. Wilens
Timothy E. Wilens
Stimulants are part of the standard-of-care treatment for attention-deficit/hyperactivity disorder (ADHD). Methylphenidate, with a history of use spanning approximately 5 decades, is a first-line stimulant treatment for ADHD. Methylphenidate chiefly affects the prefrontal cortex and striatum, the mechanism of action being modulation of catecholaminergic tone. Methylphenidate treatment produces an increase in dopamine (DA) signaling through multiple actions, including blockade of the DA reuptake transporter and amplification of DA response duration, disinhibition of DA D2 autoreceptors and amplification of DA tone, and activation of D1 receptors on the postsynaptic neuron. The actions of methylphenidate may also be mediated by stimulation of the noradrenergic alpha2 receptor and DA D1 receptor in the cortex. The role of other neurotransmitters such as histamine, acetylcholine, serotonin, and alpha-agonists in modulating catecholamine pathophysiology in ADHD and ADHD treatment needs to be elucidated. Overall, the changes in catecholaminergic tone clinically manifest as improvements in attention deficit, distractibility, and motor hyperactivity in patients with ADHD.